Hong Kong Stock Connect Movement | Lepu Biopharma surges over 14%, with institutions indicating strong performance overseas, aligning with the main investment theme of "medical industry going global + innovation"

NightAirdropper · 2026-04-03T05:37:26+00:00

Lepu Biopharmaceutical's stock price surged over 14%, with a market capitalization of HKD 10.989 billion. The company's revenue in 2025 is projected to reach RMB 935 million, a year-on-year increase of 250%. Three products have been successfully authorized, covering multiple fields including immunotherapy. It is expected that future revenue and net profit will continue to grow, maintaining a "Buy" rating.

NightAirdropper

2026-04-03 05:37:26

Abstract generation in progress

Lepu Biotech (2157.HK) surged more than 14%, closing at HK$6.09, with a total market value of HK$10.989 billion. Lepu Biotech recently released its 2025 full-year results. During the reporting period, the company generated revenue of RMB 935 million, about 2.5 times that of 2024. Among that, in terms of domestic commercialization, the company’s sales of Pu You Heng® (pertuzumab injection) and Mei You Heng® (vedibekcotar ta single-antibody injection) generated revenue of approximately RMB 501 million, up 66.8% year over year.

In a research note commenting on Lepu Biotech’s 2025 annual performance, Guolian Minsheng Securities said that the company’s three products have successfully achieved external licensing cooperation. Lepu Biotech’s pipeline covers three major areas: immunotherapy, ADC targeted therapy, and oncolytic virus drugs. It includes 2 commercially marketed drugs, 8 clinical-stage candidate drugs (including 6 ADC products, 1 oncolytic virus product, and 1 bispecific antibody product), as well as 5 clinical-stage candidate drug combination therapies.

The firm said Lepu Biotech has made R&D plans for indications with large unmet clinical needs, such as hepatocellular carcinoma and pancreatic cancer. Multiple FIC pipelines have obtained breakthrough therapy certifications, and it is leading in its “ADC+IO” strategy. It expects the company’s operating revenue for 2026-2028 to be RMB 1.069/1.528/2.250 billion, with year-over-year growth rates of 14.3%/43.0%/47.2%; attributable net profit to be RMB 66/265/562 million; EPS to be RMB 0.04/0.15/0.31, and the current share price corresponds to PE ratios of 135/34/16 times, respectively. The company’s overseas expansion performance has been strong, which aligns with the pharmaceutical investment main theme of “going global + innovation.” It maintains a “Buy” rating. (Gelonghui)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.